Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Jagiello-Gruszfeld, A.
Tjulandin, Sergei S.
Dobrovolskava, N.
Manikhas, A.
Pienkowski, T.
Knott, A.
DeSilvio, M.
Oliva, C.
机构：
[1] Nzoz Onko Med, Olsztyn, Poland
[2] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia
[3] Russian Sci Ctr Roentgeno Radiol, Moscow, Russia
[4] St Petersburg City Oncol Dispensery, St Petersburg, Russia
[5] Inst Marii Sklodowskiej Curie, Centrum Onkol, Warsaw, Poland
[6] GlaxoSmithKline Res & Dev Ltd, London, England
[7] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246S / 246S
页数：1
相关论文
共 50 条
  • [1] Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+metastatic breast cancer
    Esteva, F. J.
    Franco, S.
    Hagan, M. K.
    Brewster, A.
    Williams, W.
    Florance, A. M.
    Koch, K.
    Turner, S. J.
    Ridderheim, M.
    Perez, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] First-line treatment patterns by age for patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry
    Jahanzeb, M.
    Tripathy, D.
    Hurvitz, S. A.
    O'Shaughnessy, J.
    Mason, G.
    Yardley, D. A.
    Brufsky, A.
    Rugo, H. S.
    Cobleigh, M.
    Swain, S. M.
    Chu, L.
    Antao, V.
    Yoo, B.
    Kaufman, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)
    Guan, Z-z
    Xu, B-h
    Arpornwirat, W.
    Tong, Z-s
    Lorvidhaya, V.
    Wang, L.
    Newstat, B.
    DeSilvio, M.
    Moore, Y.
    Shen, Z-Z
    CANCER RESEARCH, 2010, 70
  • [4] Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
    Zembryki, D.
    Gomez, H.
    Koehler, M.
    Koehler, M.
    Johnston, S.
    Pippen, J.
    Florance, A.
    O'Rourke, L.
    Maltzman, J.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [6] Safety and efficacy of lapatinib (L)-based therapy in heavily pretreated HER2+metastatic breast cancer (MBC) patients (pts): A single institution experience
    Sepulveda, J. M.
    De Velasco, G.
    Manso, L.
    Ghanem, I.
    Ciruelos Gil, E. M.
    Vega, E.
    Mendiola, C.
    Cortes-Funes, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Nanda, R.
    Krop, I. E.
    Rimawi, M. F.
    Wolff, A. C.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Najita, J. S.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Rimawi, M. F.
    Nanda, R.
    Gelman, R. S.
    Josephs, K.
    Richardson, A.
    Flores, L.
    Van Den Abbeele, A. D.
    Yap, J. T.
    Arteaga, C. L.
    Wolff, A. C.
    Krop, I. E.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Duration of lapatinib (L)-based therapy in HER2+metastatic breast cancer (MBC) in a single institution.
    Morales, Serafin
    Cud''s, Ariadna Gasol
    Salud, Antonia
    Aguirre Ortega, Elena Maria
    Derabrain, Noema A. Tuset
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345